Abstract Number: 336 • 2018 ACR/ARHP Annual Meeting
Physical Activity Monitors: New Tool to Assess Improvement in Myositis
Background/Purpose: Physical activity monitors (PAM) are increasing being used to objectively quantify free-living movement in clinical research, especially musculoskeletal diseases. Given that patients with idiopathic…Abstract Number: 373 • 2018 ACR/ARHP Annual Meeting
The Effect of an Intensive Controlled 6-Moth Exercise Program with Subsequent 6-Month Follow-up Period in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data
Background/Purpose: Muscle inflammation and weakness, subsequent atrophy and permanent muscle damage in idiopathic inflammatory myopathies (IIM) lead to impaired function, reduced muscle strength, endurance and…Abstract Number: 875 • 2018 ACR/ARHP Annual Meeting
Anti-Calreticulin Antibody – a Novel Antibody in Patients with Idiopathic Inflammatory Myopathies and Its Association with Malignancy
Background/Purpose: To investigate the occurrence of anti-calreticulin antibodies (anti-CRT Abs) and evaluate its association with malignancy in patients with idiopathic inflammatory myopathies (IIM). Methods: In…Abstract Number: 1032 • 2018 ACR/ARHP Annual Meeting
Aberrant Sarcoplasmic Expression of the Alarmin ‘High Mobility Group Box Protein 1” (HMGB1) in Patients with Idiopathic Inflammatory Myopathy
Background/Purpose: Components of the innate immune system, such a High Mobility Group Box Protein 1 (HMGB1), may contribute to the initiation, perpetuation and resolution of…Abstract Number: 2294 • 2018 ACR/ARHP Annual Meeting
Improving EULAR/Acr Classification Criteria for Idiopathic Inflammatory Myopathies
Background/Purpose: New 2016 EULAR/ACR classification criteria have been established for idiopathic inflammatory myopathies (IIM). The highest weighted score is associated with the presence of anti-Jo-1…Abstract Number: 2295 • 2018 ACR/ARHP Annual Meeting
Classification of Idiopathic Inflammatory Myopathies: Assessment of 123 Patients According to 2017 Acr/EULAR Criteria Followed up By a Single Center from Turkey
Background/Purpose: The aim of this study is to evaluate sensitivity, limitations and assessment of 2017 ACR/EULAR IIMs classification criteria (ACR/EULAR2017) in 123 patients with idiopathic…Abstract Number: 2136 • 2017 ACR/ARHP Annual Meeting
Association of HLA-DQA1*05 with the Presence of Interstitial Lung Disease Independent of Autoantibody Status in Caucasian Patients with Polymyositis and Dermatomyositis
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication and a major contributor to mortality and morbidity in polymyositis and dermatomyositis (PM/DM). Prior studies have…Abstract Number: 2146 • 2017 ACR/ARHP Annual Meeting
CD4+CXCR4+t Cells in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease
Background/Purpose: The clinical and mechanistic relevance of peripheral CD4+CXCR4+ T cells in idiopathic inflammatory myopathy (IIM)-associated interstitial lung disease (IIM-ILD) is not known. Methods: Patients…Abstract Number: 2154 • 2017 ACR/ARHP Annual Meeting
Efficacy of an Intensive 24-Week Physiotherapy Programme in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data from a Single-Center Controlled Study
Background/Purpose: Involvement of musculoskeletal system (inflammation, atrophy and permanent damage to the muscle) in idiopathic inflammatory myopathies (IIM) leads to impaired function, reduced muscle strength,…Abstract Number: 269 • 2016 ACR/ARHP Annual Meeting
The Immunoproteasomes Are Essential for Maintaining Myokine Production and MHC Class I Expression in Idiopathic Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are muscle diseases, characterized by inflammatory infiltration and increased expression of MHC class I molecules on myofibers. Immunoproteasome, as a…Abstract Number: 278 • 2016 ACR/ARHP Annual Meeting
Expression of Anti-Microbial Peptide LL-37 Correlates to the Activation of Type I Interferon Pathway in Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are systemic autoimmune diseases whose pathogenesis remain unclear. The type I interferon system has recently been suggested to have…Abstract Number: 284 • 2016 ACR/ARHP Annual Meeting
Gene-Environmental Interaction of HLA-DRB1*03:01 and Smoking for the Development of Anti-Jo-1 Autoantibodies in Idiopathic Inflammatory Myopathies: A UK Study
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and extramuscular manifestations. The most common autoantibody…Abstract Number: 1367 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes and Their Predictors in Patients with Juvenile Idiopathic Inflammatory Myopathies of Adult Age: A Referral Population Study
Background/Purpose: To investigate the long-term outcomes and prognostic factors for pts with juvenile-onset idiopathic inflammatory myopathies (JIIM) who are currently adults. Methods: Adults with JIIM…Abstract Number: 1240 • 2015 ACR/ARHP Annual Meeting
Systematic Protein-Protein Interaction and Pathway Analyses in the Idiopathic Inflammatory Myopathies
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are autoimmune diseases characterised by acquired proximal muscle weakness, inflammatory cell infiltrates in muscle and myositis-specific/associated autoantibodies (MSA/MAA). The…Abstract Number: 1251 • 2015 ACR/ARHP Annual Meeting
Physiological Evidence for Diversification of the IFNα- or IFNβ-Mediated Response Programs in Different Autoimmune Diseases
Background/Purpose: Presence of a type I interferon (IFN) signature is described for several autoimmune diseases, including systemic lupus erythematosus (SLE), multiple sclerosis (MS), myositis (IIM)…
ACR Meeting Abstracts